Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Organic Cation Transporter Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for OCTN2/SLC22A5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | OCTN2/SLC22A5 Recombinant Protein (Partial ECD) High purity (>95%), Endotoxin controlled. Sequence Verified. |
View OCTN2 Products |
| Gene Delivery | OCTN2/SLC22A5 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Crucial for preserving 12-transmembrane conformation. |
View OCTN2 Products |
| Benchmark Ab | Anti-OCTN2 Recombinant Antibody Recombinant positive control for surface expression validation. |
View OCTN2 Products |
| Validator | OCTN2/SLC22A5 siRNA Set For knockdown verification in transport assays. |
View OCTN2 Products |
| Related Target A | OCTN1 (SLC22A4) Close homolog sharing 75% sequence identity; essential for selectivity counter-screening. |
View OCTN1 Products |
| Related Target B | LAT1 (SLC7A5) Synergistic transporter target for tumor-targeted prodrug delivery strategies. |
View LAT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass transmembrane conformation preservation | Lentivirus premade particles optimized for stable cell line generation to enable functional carnitine uptake assays. |
| Subfamily counter-screening (OCTN1 vs. OCTN2) | Sequence-verified human and rodent ortholog reagents for robust selectivity profiling. |
| Lack of Controls | Clinical-grade benchmark antibodies included for assay validation. |
| False Positives | Validated siRNA sets included for target-specific knockdown controls. |
Live OCTN2/SLC22A5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of OCTN2 (SLC22A5) is expanding beyond its classical association with primary carnitine deficiency. Current drug discovery pipelines are actively exploiting OCTN2 for two main strategies: first, as a tumor-homing portal for carnitine-conjugated prodrugs (taking advantage of OCTN2 overexpression in colorectal and epithelial cancers); and second, as a key target in inflammatory bowel disease (IBD) where transporter dysfunction impairs fatty acid oxidation. In addition, FDA/EMA guidelines highlight OCTN2 as a critical transporter for ADME/Tox screening to avoid drug-induced carnitine depletion and systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Prodrug Conjugates | Academic Institutes, Biotech Startups | Colorectal Cancer, Glioblastoma | Functional Transport Assay (Need Lentivirus for Stable Cell Lines) |
| Small Molecule Inhibitors/Modulators | Pharmaceutical Developers | Metabolic Disorders, Crohn's Disease | Selectivity Assay (Need OCTN1 vs. OCTN2 panel) |
| Gene Therapy / mRNA | Rare Disease Specialists | Primary Carnitine Deficiency | Expression Validation (Need Anti-OCTN2 Benchmark Ab) |